POA Pharma is now a Galen company

Galen, the privately owned global pharmaceutical sales and marketing company, is delighted to announce the acquisition and takeover of boutique healthcare company, POA Pharma.

Proceed to POA Pharma.com Read the Press Release Visit Galen-Pharma.com
logo
Search

POA Pharma Scandinavia

  • Home
  •  
  • POA Pharma Scandinavia

POA Pharma is a young, fast growing, profitable and unique international healthcare company with its base in Scandinavia.

Brief History

POA Pharma was on the market March 2011 with offices in Gothenburg (head office), Hillerød, Bergen and Helsinki.In 2016 the company also has an office in Vancouver, WA, USA. POA has three strategic areas: The Nordics: POA Pharma has offices and marketing organisations in the four Nordic Countries. POA represents 16 producers from 10 countries. The products are placed in 9 different competence areas. Export: Products defined as Medical Nutrition, via 11 external distributors representing more than 40 countries. POA has own distribution in US and Canada via POA Pharma North America. Central Marketing & Development: POA Pharma develop products for treatment of Inborn Error of Metabolism. The products is classified as “Food for Special Medical Purposes Tactical POA works within nine areas of competence. Although a relatively young company the POA Pharma management has more than 150 years of collective experience in marketing diagnostics, nutrition, pharmaceuticals and OTC products.

A Boutique Company

POA Pharma is a market oriented Boutique Healthcare Company, working in close contact with healthcare organizations, professionals and pharmacies. Boutique is French for «shop», via Latin from Greek apothēkē, «storehouse». In contemporary business language boutique is a specialized firm with a unique concept.

“A Boutique is where you expect to be positively surprised when finding what the average shop cannot offer.“

A Flexible company

POA adapts to customer needs, and if necessary, extends its experience with associate members or specialists. This approach has implications for the way we view of our products. POA Pharma does not own the products we provide to the extent, that they must be sold at any price. We see them rather as tools to solve health care and patient problems. This approach allows us to be very flexible towards our customer.

We may not always have all the solutions to the customers’ problems but we do know where to find them.

A Research and product Developing company

Within the area of IEM we can see two trends today; More screenings in more countries resulting in more problems. Patients with PKU are getting older. Today the oldest treated PKU patient in Europe is around 45 – 50 years old. Treated patients today are not only kids and teenagers but middle aged adults and soon elderly people. The PKU society is also getting more and more differentiated and each group have their specific needs. This new situation calls for new ideas of dietary solutions and a greater variation. 2012 and 2013 POA introduced their owned PKU Concept, developed together with Scandinavian dieticians. No compromises in quality was the base for the development. In development and production terms, it means smaller quantities of more differentiated products – there is a need for “boutique thinking” a concept that differs from the classical thinking in long production series.

Tina Madsen Sandstöm (CEO)

Tina Madsen Sandström, CEO POA Pharma Scandinavia AB, Director of the board of POA Pharma Scandinavia AB, POA Pharma North America and POA Consulting Scandinavia AB. Born 1965, Merkonom. Educated at Hillerød Business School. 30 years of experience within the Pharmaceutical industry. Earlier positions: Managing Director for Pharma-Vinci A/S. Member of the branch organisation BFID. CEO for Vitaflo Scandinavia AB. Director of the board of Vitaflo Scandinavia AB.

“POA Pharma’s areas of competence reflects our ambition to be responsive.”

Our mission, to offer unique medical products of therapeutic value, is appreciated by physicians, nurses, dietitians and other healthcare professionals, as well as by the patients and their families. Our product list is constantly being extended. Several products are in the registration process. Negotiations with international manufacturers are ongoing. POA Pharma contributes to better healthcare, better health and wellbeing and a higher quality of life.

At present – these are our areas of competence:

  • Abuse
  • Anesthesia
  • Cardiology
  • Female Care
  • Gastro
  • ENT
  • Metabolic diseases
  • Neurology
  • Urology

A Nordic Company

POA Pharma is a Pharmaceutical and Healthcare company with its base in Scandinavia. Scandinavia is our home market with offices and sales forces in Denmark, Finland, Norway and Sweden (Head office). We know and have long experiences with the Nordic healthcare markets and are familiar with the rules and regulations issued by the national and regional medical and pharmaceutical agencies.

Poa_Top_Eng

There is a reason why we’re called POA Pharma Scandinavia. POA scan the four Nordic markets!

An International Company

POA Pharma collaborates with POA Consulting the main owner of POA Pharma. POA consulting founded and operates GHN, Global Healthcare Network that specialises in «Product and Distributor Search”. GHN is a non-profit organization that monitors together 25 countries on five continents altogether. The result of this international network is that POA Pharma has a wide selection of products from a number of producers and countries. In 2016 POA is representing, in the Nordic area, a total of 14 producers from 11 countries; Canada, Germany, Italy, India, Ireland, Japan, Schwitzerland, Spain, Sweden, UK, USA POA via affiliates also distributes its own metabolic assortment in countries outside the Nordics; Australia, Argentina,Algeria, Bahrain, Bolivia, Brazil, Botswana, Canada, Czech Republic, Chile, Colombia, Egypt, Honduras, Iraq, Ireland, Jordan, Italy, Kuwait, Lebanon, Libya, Malaysia, Marrocco, Mexico, Mosambique, Namibia, Netherlands, New Zeeland, Oman, Quatar, Palestinian Territories,Thailand, Tunisia, Saudi Arabia, Singapore, Slovakia, South Africa, South Korea, Sudan, South Sudan, Syria, Turkey, UK, USA (POA Pharma North America), Uruguay, United Arab EmiratesYemen, Zimbabwe. We have an interface comparable to that of big Pharma, making us better known abroad than at home. The contacts provide benefits as well as a broad and updated assortment. Despite our relatively small size, we can offer a larger number of drugs and health care products within nine areas of competence.

No coincidence

POA Pharma’s successful export business is no coincidence.It reflects Roland Sandström’s 40 years of experience in several positions in the international pharmaceutical industry.

“I’d like to quote a report from Price Warterhouse Coopers, Pharma 2020 Marketing the future saying: By 2020 the current role of the pharmaceutical industry’s sales and marketing workforce will be replaced by a new model as the industry shifts from a mass-market to a target-market approach to increase revenue.”

–I say we are already there!

Roland

Roland Sandström (COB)

Roland Sandström, chairman of the board of POA Scandinavia AB, POA Pharma North America, POA Consulting Scandinavia AB. Born 1946. Founder and majority owner of POA Pharma Scandinavia AB. Master of political Science at the university of Lund. Articles, lectures and books (The Customer as a Friend) in organisations theory and marketing. 40 years of experience within the international Pharmaceutical industry. Earlier positions: Managing Director for Meda Sweden, board member of LSAB and LIF. COB of Vitaflo, director in the Board of Navamedic, Founder of «The Global Healthcare Network (GHN)».

© Copyright - Poa Pharma
Top